Dr. John Teerlink, MD

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Howard Hughes Med Institute

  Fellowship Hospital, 1998

• Uc San Francisco Medical Center

  Residency Hospital, 1995

• F Hoffman Laroche

  Fellowship Hospital, 1993

• Uc San Francisco Medical Center

  Internship Hospital, 1989

• Harvard Medical School

  Medical School, 1988

• Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial, 2022-04-04

• International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial, 2014-04-25

• RECURRENT STROKE IN THE WARFARIN VERSUS ASPIRIN IN REDUCED EJECTION FRACTION (WARCEF) TRIAL, 2014-10-09

• Determinants of Hemodialysis-Induced Segmental Wall Motion Abnormalities, 2013-11-14

• Resting heart rate and ischemic stroke in patients with heart failure, 2017-04-19

• Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication, 2011-05-25

• Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data from the WARCEF trial, 2016-06-28

• Heart Failure Site-Based Research in the United States: Results of the Heart Failure Society of America Research Network Survey, 2019-04-10

• Associations of Tissue Doppler Imaging with NT-proBNP and hs-TnT: A Pilot Study in End-Stage Renal Disease, 2014-03-28

• Letter by Teerlink et al Regarding Article, "The Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity”, 2015-07-22

• Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study, 2016-11-12

• Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial Differential Response in Acute Heart Failure, 2017-06-27

• Heart Failure Endpoints in Cardiovascular Outcome Trials of SGLT2 inhibitors in Patients with Type 2 Diabetes: A Critical Evaluation of Clinical and Regulatory Issues, 2019-12-16

• Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial, 2015-06-17

• Reassessing the Role of Surrogate Endpoints in Drug Development for Heart Failure, 2018-09-04

• Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program, 2016-09-15

• A combined clinical and biomarker approach to predict diuretic response in acute heart failure, 2015-08-18

• Stroke in Heart Failure in Sinus Rhythm: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial, 2013-07-30